MA30821B1 - Derives de pyrazoline utiles comme antagonistes des recepteurs de mineralocorticoïdes - Google Patents

Derives de pyrazoline utiles comme antagonistes des recepteurs de mineralocorticoïdes

Info

Publication number
MA30821B1
MA30821B1 MA31831A MA31831A MA30821B1 MA 30821 B1 MA30821 B1 MA 30821B1 MA 31831 A MA31831 A MA 31831A MA 31831 A MA31831 A MA 31831A MA 30821 B1 MA30821 B1 MA 30821B1
Authority
MA
Morocco
Prior art keywords
antagonists
derivatives useful
pyrazoline derivatives
mineralocorticoid receptors
compounds
Prior art date
Application number
MA31831A
Other languages
English (en)
Inventor
Marvin Jay Meyers
Graciela Barbieri Arhancet
Xiangyang Chen
Susan Landis Hockerman
Scott Allen Long
Matthew William Mahoney
David Bruce Reitz
Joseph Gerace Rico
Original Assignee
Pfizer Products Inc Etat De Connecticut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc Etat De Connecticut filed Critical Pfizer Products Inc Etat De Connecticut
Publication of MA30821B1 publication Critical patent/MA30821B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

L'INVENTION CONCERNE DES COMPOSÉS ET DES SELS PHARMACEUTIQUEMENT ACCEPTABLES DES COMPOSÉS, CES DERNIERS AYANT LA STRUCTURE REPRÉSENTÉE PAR LA FORMULE I: DANS LAQUELLE R1, R2, R3A, R3B, R4, R5, R6, R7, R8 ET X SONT TELS QUE DÉFINIS DANS LA DESCRIPTION DÉTAILLÉE DE L'INVENTION. L'INVENTION CONCERNE ÉGALEMENT DES COMPOSITIONS PHARMACEUTIQUES CORRESPONDANTES, DES PROCÉDÉS DE TRAITEMENT CORRESPONDANTS ET DES INTERMÉDIAIRES CORRESPONDANTS.
MA31831A 2006-10-31 2009-04-30 Derives de pyrazoline utiles comme antagonistes des recepteurs de mineralocorticoïdes MA30821B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US86360606P 2006-10-31 2006-10-31

Publications (1)

Publication Number Publication Date
MA30821B1 true MA30821B1 (fr) 2009-10-01

Family

ID=39027523

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31831A MA30821B1 (fr) 2006-10-31 2009-04-30 Derives de pyrazoline utiles comme antagonistes des recepteurs de mineralocorticoïdes

Country Status (40)

Country Link
US (3) US7781428B2 (fr)
EP (1) EP2089367B1 (fr)
JP (1) JP4977760B2 (fr)
KR (1) KR101107800B1 (fr)
CN (1) CN101541757A (fr)
AP (1) AP2527A (fr)
AR (1) AR063529A1 (fr)
AT (1) ATE537151T1 (fr)
AU (1) AU2007315884B2 (fr)
BR (1) BRPI0717937A2 (fr)
CA (1) CA2667966C (fr)
CL (1) CL2007003154A1 (fr)
CO (1) CO6160307A2 (fr)
CR (1) CR10725A (fr)
CU (1) CU23779B7 (fr)
CY (1) CY1112311T1 (fr)
DK (1) DK2089367T3 (fr)
EA (1) EA016370B1 (fr)
ES (1) ES2375877T3 (fr)
GE (1) GEP20115239B (fr)
GT (1) GT200700096A (fr)
HN (1) HN2007000437A (fr)
HR (1) HRP20120078T1 (fr)
IL (1) IL198241A0 (fr)
MA (1) MA30821B1 (fr)
MX (1) MX2009004662A (fr)
MY (1) MY145795A (fr)
NI (1) NI200900071A (fr)
NO (1) NO20091741L (fr)
NZ (1) NZ575923A (fr)
PE (1) PE20081472A1 (fr)
PL (1) PL2089367T3 (fr)
PT (1) PT2089367E (fr)
RS (2) RS52203B (fr)
SI (1) SI2089367T1 (fr)
TN (1) TN2009000160A1 (fr)
TW (1) TWI357327B (fr)
UA (1) UA92670C2 (fr)
UY (1) UY30670A1 (fr)
WO (1) WO2008053300A1 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20091057A1 (es) 2007-12-19 2009-07-20 Lilly Co Eli Antagonistas del receptor mineralcorticoide y metodos de uso
CN102686571B (zh) * 2009-10-29 2015-11-25 百时美施贵宝公司 三环杂环化合物
CA2796307A1 (fr) 2010-05-10 2011-11-17 Inserm (Institut National De La Sante Et De La Recherche Medicale) Procedes et compositions pour le traitement de l'accumulation de fluides dans et/ou sous la retine
JP2013528598A (ja) 2010-05-11 2013-07-11 ファイザー・インク ミネラルコルチコイド受容体拮抗薬としてのモルホリン化合物
JP6180930B2 (ja) 2010-06-16 2017-08-16 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 創傷治癒過程における再上皮化を刺激するための方法及び組成物
CN102372710A (zh) * 2010-08-18 2012-03-14 山东轩竹医药科技有限公司 作为盐皮质激素受体拮抗剂的并环类化合物
WO2012048022A2 (fr) * 2010-10-05 2012-04-12 Nova Southeastern University Procédés et compositions pour la modulation thérapeutique des taux d'aldostérone dans une maladie cardiaque
SI3160948T1 (sl) 2014-06-30 2020-06-30 Astrazeneca Ab Amidi benzoksazinona, kot modulatorji receptorja mineralokortikoida
US20180280414A1 (en) 2015-10-13 2018-10-04 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for the treatment of choroidal neovascularisation
EP3490606B8 (fr) 2016-07-26 2024-04-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Antagoniste des récepteurs des minéralocorticoïdes pour le traitement de l'arthrose
ES2859478T3 (es) 2016-09-02 2021-10-04 Bristol Myers Squibb Co Compuestos heterocíclicos tricíclicos sustituidos
WO2019032632A1 (fr) 2017-08-09 2019-02-14 Bristol-Myers Squibb Company Composés d'alkylphényle
US11059784B2 (en) 2017-08-09 2021-07-13 Bristol-Myers Squibb Company Oxime ether compounds
WO2021180818A1 (fr) 2020-03-11 2021-09-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédés permettant de déterminer si un sujet a ou risque d'avoir une choriorétinopathie séreuse centrale
WO2023031277A1 (fr) 2021-08-31 2023-03-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthodes de traitement de la rosacée oculaire
CN113679716B (zh) 2021-10-13 2024-03-26 史大永 溴酚-吡唑啉化合物在治疗猫冠状病毒疾病中的应用
CN114230457B (zh) * 2022-01-04 2023-06-09 中山大学 一类2-亚苄基四氢萘酮衍生物及其制备方法和应用

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1086068A (en) * 1964-09-02 1967-10-04 Ici Ltd Process for the whitening of polymeric materials and nitrogen-containing polycyclic compounds for use therein
BE789948A (fr) * 1971-10-13 1973-04-11 Sandoz Sa Nouveaux derives du pyrazole, leur preparation et leur application comme medicaments
US3816438A (en) * 1972-12-22 1974-06-11 Sandoz Ag 2h(1)-benzothiepino(5,4-c)-pyrazoles and(1)-benzothiopyrano(4,3-c)-pyrazoles
US3843666A (en) * 1973-05-29 1974-10-22 Sandoz Ag Process for preparing substituted indeno,naphtho and cyclohepta pyrazoles
US4866025A (en) * 1988-09-30 1989-09-12 Eastman Kodak Company Thermally-transferable fluorescent diphenylpyrazolines
JP2813464B2 (ja) * 1992-01-23 1998-10-22 フアイザー・インコーポレイテツド ベンゾピラン及び関連ｌｔｂ▲下４▼アンタゴニスト
GB9318691D0 (en) 1993-09-09 1993-10-27 Merck Sharp & Dohme Therapeutic agents
ID16283A (id) 1996-03-20 1997-09-18 Astra Pharma Prod Senyawa yang berguna dibidang farmasi
WO1998009969A1 (fr) * 1996-09-05 1998-03-12 Astra Pharmaceuticals Ltd. Nouveaux aryle-pyridazines
JPH10273467A (ja) * 1997-01-29 1998-10-13 Snow Brand Milk Prod Co Ltd 新規テトラロン又はベンゾピラノン誘導体及びその製造方法
IT1292092B1 (it) 1997-06-05 1999-01-25 Geange Ltd Impiego di derivati eterociclici aromatici azotati nel trattamento topico di affezioni di tessuti epiteliali
WO1999055335A1 (fr) 1998-04-30 1999-11-04 Basf Aktiengesellschaft Derives substitues de pyrazole tricyclique exerçant une activite de proteine kinase
US6432974B1 (en) * 2000-02-04 2002-08-13 Wyeth Pyrrolo-isoquinoline and tetra-hydropyrrolo-isoquinoline derivatives and their use as mediators of the 5-HT7 receptor
AU2003249597B2 (en) 2002-03-08 2007-06-28 Merck Sharp & Dohme Corp. Mitotic kinesin inhibitors
WO2003078394A1 (fr) 2002-03-15 2003-09-25 Eli Lilly And Company Derives de dihydroindol-2-one modulant le recepteur nucleaire de l'hormone steroide
TW200400816A (en) 2002-06-26 2004-01-16 Lilly Co Eli Tricyclic steroid hormone nuclear receptor modulators
ES2273043T3 (es) 2002-08-02 2007-05-01 Vertex Pharmaceuticals Incorporated Composiciones de pirazol utiles como inhibidores de gsk-3.
OA12929A (en) 2002-09-18 2006-10-13 Pfizer Prod Inc Pyrazole derivatives as transforming growth (TGF) inhibitors.
CN1742007A (zh) 2003-01-22 2006-03-01 伊莱利利公司 甾族激素核受体的吲哚衍生物调控剂
ES2308296T3 (es) 2003-12-19 2008-12-01 Eli Lilly And Company Modulares del receptor nuclear de hormonas esteroideas triciclicas.
JP2007230869A (ja) 2004-04-05 2007-09-13 Takeda Chem Ind Ltd アルドステロン受容体拮抗剤
WO2006010142A2 (fr) 2004-07-14 2006-01-26 Ligand Pharmaceuticals, Inc. Composes de modulation des recepteurs des mineralocorticoides et methodes associees
US8026237B2 (en) 2004-07-30 2011-09-27 Exelixis, Inc. Pyrrole derivatives as pharmaceutical agents
CA2593156C (fr) 2005-01-10 2015-05-05 Exelixis, Inc. Composes carboxamides heterocycliques utilises ent ant qu'agents pharmaceutiques
JPWO2006077821A1 (ja) 2005-01-19 2008-06-19 大日本住友製薬株式会社 アルドステロン受容体調節剤としての芳香族スルホン化合物
AU2006212863A1 (en) 2005-02-10 2006-08-17 Merck Sharp & Dohme Corp. Mitotic kinesin inhibitors

Also Published As

Publication number Publication date
AR063529A1 (es) 2009-01-28
PT2089367E (pt) 2012-02-01
IL198241A0 (en) 2009-12-24
AP2527A (en) 2012-12-06
US20100280016A1 (en) 2010-11-04
ATE537151T1 (de) 2011-12-15
CA2667966A1 (fr) 2008-05-08
CR10725A (es) 2009-05-12
JP4977760B2 (ja) 2012-07-18
BRPI0717937A2 (pt) 2013-12-03
EP2089367A1 (fr) 2009-08-19
CA2667966C (fr) 2011-08-02
CN101541757A (zh) 2009-09-23
EA016370B1 (ru) 2012-04-30
MY145795A (en) 2012-04-30
RS52203B (sr) 2012-10-31
CU23779B7 (es) 2012-02-15
AU2007315884B2 (en) 2012-10-04
PL2089367T3 (pl) 2012-04-30
CL2007003154A1 (es) 2008-05-09
WO2008053300A1 (fr) 2008-05-08
EP2089367B1 (fr) 2011-12-14
US7781428B2 (en) 2010-08-24
TW200822924A (en) 2008-06-01
PE20081472A1 (es) 2008-10-18
AP2009004822A0 (en) 2009-04-30
UY30670A1 (es) 2008-05-31
NO20091741L (no) 2009-05-29
KR20090060371A (ko) 2009-06-11
JP2010508257A (ja) 2010-03-18
NI200900071A (es) 2010-03-08
TWI357327B (en) 2012-02-01
HRP20120078T1 (hr) 2012-02-29
CY1112311T1 (el) 2015-12-09
KR101107800B1 (ko) 2012-01-25
GEP20115239B (en) 2011-06-10
DK2089367T3 (da) 2012-02-06
RS20090208A (sr) 2010-06-30
GT200700096A (es) 2010-07-15
ES2375877T3 (es) 2012-03-07
UA92670C2 (ru) 2010-11-25
US20080167294A1 (en) 2008-07-10
CO6160307A2 (es) 2010-05-20
MX2009004662A (es) 2009-05-22
AU2007315884A1 (en) 2008-05-08
SI2089367T1 (sl) 2012-02-29
EA200970341A1 (ru) 2009-10-30
NZ575923A (en) 2011-01-28
TN2009000160A1 (fr) 2010-10-18
HN2007000437A (es) 2011-01-17
US20120035131A1 (en) 2012-02-09
CU20090058A7 (es) 2011-07-11

Similar Documents

Publication Publication Date Title
TN2009000160A1 (fr) Derives de pyrazoline utiles comme antagonistes des recepteurs de mineralocorticoides
MA32070B1 (fr) Dérivés hétérocycliques réunis par fusion et procédés d'utilisation associés
MA29909B1 (fr) Derives de pyridazine
MA34819B1 (fr) Dérivés bicyclo[3.2.1]octylamide et leurs utilisations
MA30352B1 (fr) Pyridine [3,4-b] pyrazinones
ECSP099755A (es) Derivados de pirrolopiridina y su uso como inhibidores de bace
EA200870193A1 (ru) Цитотоксические агенты, включающие новые производные томаймицина, и их терапевтическое применение
MA31906B1 (fr) Inhibiteurs de la replication du virus de limmunodeficience humaine
MA31373B1 (fr) Composes amino-heterocycliques
MA35749B1 (fr) Dérivés nucléosidiques 4'-azido, 3'-fluoro substitués en tant qu'inhibiteurs de la réplication de l'arn du vhc
MA30722B1 (fr) Utilisation de derives de l'adenosine en tant qu'agonistes du recepteurs a2a
UY29919A1 (es) Derivados sustituidos de 3,4-dihidroisoquinolin-1-amino-trifluoroacetato, sus composiciones farmacéuticas y aplicaciones
MA30291B1 (fr) Derives de l'azolopyridin-3-one en tant qu'inhibiteurs de la lipase endotheliale
MA31593B1 (fr) Derives de 2-aza-bicyclo[3.3.0]octane
MA32711B1 (fr) Pyrrolidine-2-carboxamides substitues
ECSP088871A (es) Derivados de triazolopirazina
ECSP088972A (es) Isoindoles sustituidos como inhibidores de bace y su uso
ATE537175T1 (de) Neue piperazino-dihydrothienopyrimidin-derivate
TW200728307A (en) Novel spirochromanone derivatives
UY31083A1 (es) Derivados de sulfoximinas para la inhibicion de b-secretasa
MA31158B1 (fr) Composes tricycliques et leur utilisation comme modulateurs du recepteur de glucocorticoïdes
MA30703B1 (fr) Dérivés de 5,6-bisaryl-2-pyridine-carboxamide, leur préparation et leur application en thérapeutique comme antagonistes des recepteurs a l'urotensine ii.
MA37891A1 (fr) Alcoxypyrazoles comme activateurs de guanylate cyclase soluble
MA37886B1 (fr) Nouvelles pyridinones bicycliques
EA200870302A1 (ru) 1,3-диоксанкарбоновые кислоты